Huge news in APOL1 nephropathy - ten tweets to fill you in here:

Welcome to #TenTweetNephJC

✳️10 tweets #NephJC catch-up ✳️

On 4/25-26, we discussed the phase II study examining inaxaplin treatment, a small molecule inhibitor, in APOL1 nephropathy. This is the first drug specifically targeting this disease.

Join us here for the recap! pic.twitter.com/LApAHkYn10
— Nephrology Journal Club (@NephJC) May 12, 2023